The Journal of Infectious Disease publication reports the most recent results from Colby’s lead cationic lipid-DNA complex (CLDC), JVRS-100. JVRS-100 has now been shown to be an important adjuvant to enhance immune response [humoral (IgG and IgA)] against human influenza vaccine. The results show that Colby’s JVRS-100 adjuvant, when used in combination with an influenza virus vaccine (the Fluzone 2006-2007 seasonal influenza virus vaccine, (including influenza A/New Caledonia/20/99(H1N1) antigen), generates enhanced immunity and superior protection of elderly Rhesus Macques monkeys when challenged with live human flu virus (relative to the Fluzone vaccine alone).
“The Colby data that was just published in the Journal of Infectious Disease clearly shows the remarkable enhancement of immunity from the JVRS-100 added to the human influenza vaccine Fluzone, as measured by the anti-influenza immune responses. There was a dramatic decrease in virus infection in the monkeys inoculated with the JVRS-100 vaccine. Influenza viral replication was completely, or nearly completely, undetectable,” stated David B. Lewis, M.D., an immunologist at Stanford University and Chairman of the Colby Scientific Advisory Board.
In addition, it is remarkable that after a live flu virus challenge, only the JVRS-100 immunized monkeys had significantly lower levels of virus replication (p<0.01) relative to the control animals who were not immunized with JVRS-100. For example, peak levels of the flu virus were 100-fold lower in the respiratory tract secretions of elderly rhesus monkeys inoculated with Fluzone vaccine with the JVRS-100 added, as compared to the Fluzone vaccine alone monkeys.
Colby’s Chief Executive Officer, David Zarling, Ph.D., MBA, remarked that, “This newly published data, from Colby’s recently completed NIH National Institute of Allergy and Infectious Diseases (NIAID)-funded team, is compelling and timely. These well-controlled experime
Copyright©2012 Vocus, Inc.
All rights reserved